Stuttgart Stock Exchange launches pan-European tokenized asset platform
Jinse Finance reported that the Stuttgart Stock Exchange Group, the sixth largest exchange operator in Europe, has launched Seturion, a blockchain-based settlement platform capable of handling pan-European cross-border tokenized asset transactions. The platform supports both public and private chains and allows settlements in central bank money or on-chain cash, targeting institutions such as banks and brokers. The platform has already completed testing in collaboration with the European Central Bank, and BX Digital, the Swiss compliant DLT trading platform under the Stuttgart Stock Exchange, has been put into operation. Currently, multiple institutions in Europe are accelerating tokenization efforts, and there are also related developments in the United States, such as BlackRock launching a tokenized money market fund. Tokenization is becoming a global trend.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro: Downside risks with 1.1100 in sight against US Dollar – ING
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
